Baseline characteristics of patients with cHL treated with BV + AVD
| Characteristics . | Overall (n = 153), n (%) . |
|---|---|
| Median age, y (range) | 35 (18-76) |
| >60 y | 33 (22%) |
| Sex | |
| Male | 93 (61%) |
| cHL stage | |
| I-II | 13 (8%) |
| III-IV | 140 (92%) |
| Histology | |
| Nodular sclerosis | 101 (66%) |
| Mixed cellularity | 18 (12%) |
| Lymphocyte-rich | 7 (5%) |
| Unknown/not available | 27 (18%) |
| ECOG status | |
| 0 | 80 (52%) |
| 1 | 58 (38%) |
| 2 | 10 (7%) |
| 3-4 | 4 (3%) |
| IPS (advanced-stage patients only) | |
| 0-3 | 82 (59%) |
| 4-7 | 57 (41%) |
| Comorbidities | |
| PN | 9 (6%) |
| Diabetes mellitus | 8 (5%) |
| Pulmonary disease | 15 (10%) |
| HIV infection | 7 (5%) |
| Cardiovascular disease | 16 (10%) |
| None | 86 (56%) |
| Meets ≥1 exclusion criteria for ECHELON-1 | 34 (22%) |
| Median number of cycles BV + AVD (range) | 6 (1-6) |
| Median starting dose, mg/kg (range) | 1.2 (0.9-1.2) |
| Median number of treatments BV received (range) | 11 (1-12) |
| Characteristics . | Overall (n = 153), n (%) . |
|---|---|
| Median age, y (range) | 35 (18-76) |
| >60 y | 33 (22%) |
| Sex | |
| Male | 93 (61%) |
| cHL stage | |
| I-II | 13 (8%) |
| III-IV | 140 (92%) |
| Histology | |
| Nodular sclerosis | 101 (66%) |
| Mixed cellularity | 18 (12%) |
| Lymphocyte-rich | 7 (5%) |
| Unknown/not available | 27 (18%) |
| ECOG status | |
| 0 | 80 (52%) |
| 1 | 58 (38%) |
| 2 | 10 (7%) |
| 3-4 | 4 (3%) |
| IPS (advanced-stage patients only) | |
| 0-3 | 82 (59%) |
| 4-7 | 57 (41%) |
| Comorbidities | |
| PN | 9 (6%) |
| Diabetes mellitus | 8 (5%) |
| Pulmonary disease | 15 (10%) |
| HIV infection | 7 (5%) |
| Cardiovascular disease | 16 (10%) |
| None | 86 (56%) |
| Meets ≥1 exclusion criteria for ECHELON-1 | 34 (22%) |
| Median number of cycles BV + AVD (range) | 6 (1-6) |
| Median starting dose, mg/kg (range) | 1.2 (0.9-1.2) |
| Median number of treatments BV received (range) | 11 (1-12) |